Teva Pharmaceutical unit's 0.25% debentures convertible until Nov. 11

By Angela McDaniels

Tacoma, Wash., Aug. 9 - Teva Pharmaceutical Industries Ltd. subsidiary Teva Pharmaceutical Finance II, LLC said its 0.25% series B convertible senior debentures due 2024 will be convertible into American Depositary Receipts from Aug. 12 until Nov. 11.

The conversion price is $34.1194 per ADR, which is equal to a conversion ratio of 29.3088 ADRs per $1,000 principal amount of debentures.

The company's ADRs (Nasdaq: TEVA) closed at $39.76 on Aug. 9.

In May, the company said the debentures were convertible from May 13 until Aug. 12.

Teva makes generic and human pharmaceuticals as well as active pharmaceutical ingredients. The company is based in Petach Tikva, Israel

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.